For the third consecutive year, NewYork-Presbyterian/Weill Cornell Medical Center has been recognized with the Mitral Valve Repair Reference Center Award by the Mitral Foundation for demonstrated excellence in heart valve repair.

A new study reveals that some men who are diagnosed “grade group one” (GG1) prostate cancer may actually be at higher risk than biopsy results suggest, according to research led by Weill Cornell Medicine, University Hospitals Cleveland and Case Western University.

By understanding differences in how people’s brains are wired, clinicians may be able to predict who would benefit from a self-guided anxiety care app, according to a new analysis from a clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.

NewYork-Presbyterian Hospital has once again been recognized as one of the best hospitals in the nation and a #1 hospital in New York by U.S. News & World Report. This is the 22nd year in a row that the Hospital has been named among the top hospitals in the nation.

With the help of artificial intelligence (AI), an inexpensive test found in many doctors’ offices may soon be used to screen for hidden heart disease.

Emile Bacha, M.D., chief of the Division of Cardiac, Thoracic, and Vascular Surgery at NewYork-Presbyterian and Columbia, has been named 106th president of the American Association for Thoracic Surgery (AATS), an international professional organization dedicated to advancing innovation in the care and treatment of cardiothoracic disease.

A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid biopsy blood tests for early detection of a treatment-resistance mutation, followed by a switch to a new type of treatment, substantially extends the period of tumor control compared to standard care.

Entrepreneur Mike Repole is giving back to his home community with a $16 million gift to NewYork-Presbyterian to transform cancer care for all in New York City’s most diverse borough.